The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The impact of rusfertide on PV-related symptoms & patient-reported outcomes in the VERIFY trial
In this video, Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, briefly discusses the benefits of rusfertide for patients with polycythemia vera (PV) observed in the VERIFY trial (NCT05210790). He highlights patient-reported outcomes and quality of life improvements, particularly reductions in fatigue. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, within the VERIFY trial, we were able to verify the benefit that the patients receiving rusfertide had in terms of many items related to patient-reported outcomes and quality of life. The most striking one was probably related to fatigue. And fatigue is an item that can benefit from rusfertide since it has a great major impact on iron metabolism so avoiding phlebotomies and avoiding all the process that brings to iron depletion in those patients can obviously result in a benefit with respect to stamina with respect to energy, with respect to lack of fatigue...
Well, within the VERIFY trial, we were able to verify the benefit that the patients receiving rusfertide had in terms of many items related to patient-reported outcomes and quality of life. The most striking one was probably related to fatigue. And fatigue is an item that can benefit from rusfertide since it has a great major impact on iron metabolism so avoiding phlebotomies and avoiding all the process that brings to iron depletion in those patients can obviously result in a benefit with respect to stamina with respect to energy, with respect to lack of fatigue. And I think that this will be a game changer for all the patients receiving phlebotomies right now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
